Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutical and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer.
Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
The news comes after Veranova recently announced expansion – estimated at $30 million – of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities.
A seasoned commercial and business executive, Cécile brings a deep understanding of contract development and manufacturing organizations (CDMO) and the pharmaceutical industry. Her proven track record of building teams and transforming organizations and extensive experience across multiple drug modalities will ensure Cécile is an integral part of Veranova’s continued growth.
“I’m delighted to have Cécile join the Veranova team as our Chief Commercial Officer” said Mike Riley, Chief Executive Officer of Veranova. “Her expertise and track record in building and growing businesses will be invaluable as Veranova continues to execute our strategy to build a world-class CDMO.”
source: Chemanager-online.com
Pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease.
Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients, including those for its approved Alzheimer’s treatment.
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.
